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Abstract
Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other genetic
mutations to the disease is largely unknown. Here, we describe the first completely sequenced
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genome from a Burkitt lymphoma tumor and germline DNA from the same affected individual.
We further sequenced the exomes of 59 Burkitt lymphoma tumors and compared them to
sequenced exomes from 94 diffuse large B-cell lymphoma (DLBCL) tumors. We identified 70
genes that were recurrently mutated in Burkitt lymphomas, including ID3, GNA13, RET, PIK3R1
and the SWI/SNF genes ARID1A and SMARCA4. Our data implicate a number of genes in
cancer for the first time, including CCT6B, SALL3, FTCD and PC. ID3 mutations occurred in
34% of Burkitt lymphomas and not in DLBCLs. We show experimentally that ID3 mutations
promote cell cycle progression and proliferation. Our work thus elucidates commonly occurring
gene-coding mutations in Burkitt lymphoma and implicates ID3 as a new tumor suppressor gene.
Burkitt lymphoma is characterized by deregulation of the MYC gene through its
translocation to one of the immunoglobulin loci. The role of collaborating genetic mutations
that contribute to Burkitt lymphoma remains unknown1,2. Whereas gene expression profiles
of Burkitt lymphoma and the more common DLBCL have shown that these two diseases
have vast molecular differences1,3, the genetic underpinnings of these differences are not
known.
We identified a classic case of Burkitt lymphoma4 and performed whole-genome sequencing
of tumor and germline DNA from the same affected individual using the Illumina platform.
The distribution of somatic mutations observed in the Burkitt lymphoma genome is depicted
in a Circos5 diagram (Fig. 1; summarized in Supplementary Table 1). The vast majority of
somatic alterations were in intergenic regions. We observed 6 mutations in potential
regulatory regions (loci within 2 kb of a transcriptional start site) and 42 in gene-coding
regions. Through the analysis of paired-end reads6, we also identified the presence of the
t(8;14) translocation (Supplementary Fig. 1) that is a defining feature of Burkitt lymphoma.
Thus, in this single genome, nearly all the known hallmarks of Burkitt lymphoma were
identified, including the translocation and mutation of the MYC gene.
We further characterized the diversity of mutations in Burkitt lymphoma by performing
exome sequencing on 59 affected individuals, including 51 primary Burkitt lymphoma
tumors, 14 with paired normal tissue, and 8 Burkitt lymphoma cell lines, using the Illumina
platform and Agilent reagents. We verified adequate sequencing quality and coverage
throughout the exome (Supplementary Fig. 2). We identified genetic variants and further
classified these as synonymous, missense, nonsense and small insertions and/or deletions
(indels).
We verified the accuracy of genetic variant identification from our deep sequencing data by
performing Sanger sequencing on 108 missense and 16 frameshift and/or indel mutations
(Supplementary Note). We found that the two methods agreed for over 80% of the variants
assessed (Supplementary Table 2), confirming that our sequencing and bioinformatics
methods generated accurate results.
We designated the 14 Burkitt lymphoma samples with paired germline DNA our discovery
set, and the remaining 45 Burkitt lymphoma samples were designated the validation set. We
noted that transitions were the predominant form of somatically acquired genetic variation in
the discovery set (P < 1 × 10−6, χ2 test; Fig. 2a and Supplementary Fig. 3)7. We identified
1,241 variants in 1,104 unique genes that were somatically mutated in at least 1 tumor-
germline pair in the discovery set. We then identified additional genetic variants for these
1,104 genes in the validation set, which were similarly rare variants that were not present in
databases of normal variation, including dbSNP135 (ref. 8), publicly available data from
healthy individuals9–12 (Supplementary Note) and data from 19 additional exomes that we
sequenced from control individuals without lymphoma.
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For the 1,104 somatically mutated genes, we identified candidate mutated genes in the
validation set of 45 Burkitt lymphomas. We annotated the 2,318 variants that were
nonsynonymous and did not occur in normal controls. For a gene to be classified as being
mutated in Burkitt lymphoma, it needed to have recurrent variants that were already in the
Catalogue of Somatic Mutations in Cancer (COSMIC)13 or recurrent variants in close
proximity to each other or affecting the same protein domain (Supplementary Fig. 4 and
Supplementary Note).
We identified 70 recurrently mutated genes in Burkitt lymphoma (Supplementary Tables 3
and 4), including 16 genes that have been conclusively implicated in cancer13. The number
and types of mutations in genes that were mutated in 10% or more of the Burkitt lymphomas
(n = 19) are shown (Fig. 2b,c). We noted considerable heterogeneity in the number of
mutated genes, which ranged up to 16 per lymphoma of these 70 genes (Fig. 2d). Gene
expression data confirmed that all of these genes were measurably expressed in Burkitt
lymphomas, DLBCLs or mature B cells (an example of expression is depicted in
Supplementary Fig. 5).
The most frequently mutated genes in Burkitt lymphoma were MYC (40%) and ID3 (34%).
Other frequently mutated genes included the known suppressor genes ARID1A, SMARCA4
and TP53, as well as the oncogene PIK3R1 and NOTCH1. In the recurrently mutated genes
in Burkitt lymphoma, silencing events, such as nonsense and frameshift mutations,
constituted a substantial proportion (∼30% or more) of the events in ID3, GNA13, ARID1A,
CREBBP and CCT6B, suggesting that the genetic alterations may result in loss of function.
We further investigated the genetic differences between Burkitt lymphoma and DLBCL.
Through similar analyses, we identified 351 recurrently mutated genes in DLBCL
(Supplementary Note and J.Z. et al., unpublished data), a number of which overlapped with
those identified in previously published studies of DLBCL14–16. We identified all genes that
were recurrently mutated in either Burkitt lymphoma or DLBCL at a frequency of at least
10% in our study or one of the published studies of DLBCL. We plotted the relative and
absolute frequencies of the gene alterations in Burkitt lymphoma and DLBCL (Fig. 3a,b).
We found a number of genes, including ID3, MYC, TPST2 and RET, that were
predominantly mutated in Burkitt lymphoma (P < 0.05, Fisher's exact test). In contrast,
PIM1, CECR1 and MYD88 (ref. 17) were predominantly mutated in DLBCL. A number of
genes had overlapping patterns of mutation in the two diseases, including MLL3, TP53 and
LAMA3.
We further examined the association between the occurrence of individual gene alterations
in Burkitt lymphoma and DLBCL (Fig. 3c). Notably, we found that mutations in the SWI/
SNF family members SMARCA4 and ARID1A occurred in a mutually exclusive fashion,
suggesting that mutation in one of these genes by itself may be sufficient to deregulate the
SWI/SNF chromatin-remodeling complex. The different mutational patterns of Burkitt
lymphoma and DLBCL were also related in part to the lineage-derived subsets of DLBCL18.
MYD88 and CD79A were predominantly mutated in the activated B cell–like (ABC)
DLBCLs compared to Burkitt lymphoma. GNA13, EZH2 and BCL2 showed overlapping
mutational patterns in Burkitt lymphomas and DLBCLs derived from germinal center B
cells.
ID3 mutations affected nearly a third of the Burkitt lymphomas and were not present in any
DLBCLs, including those containing MYC translocations (Supplementary Note). Nearly all
of the alterations in ID3 affected the highly conserved helix-loop-helix (HLH) domain (Fig.
4a). Of these alterations, nearly 30% represented nonsense and frameshift mutations,
suggesting that the mutations have a silencing effect on the gene.
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To better understand the biological role of ID3 mutations in Burkitt lymphoma, we began by
examining gene expression in 21 Burkitt lymphomas and 87 DLBCLs. We found that
Burkitt lymphomas were characterized by twofold higher expression of ID3 compared to
DLBCLs (P = 0.002; Supplementary Fig. 6). Both alleles seemed to be expressed at similar
levels in cases with mutations (Supplementary Fig. 7). Gene set enrichment analysis19
identified genes associated with the G1 to S-phase transition as being significantly
upregulated in lymphomas with ID3 mutations (false discovery rate (FDR) < 0.05;
Supplementary Fig. 8). The expression of cell cycle pathway genes corresponding to the G1
to S-phase transition, including E2F1, CDK7 and MCM10, was significantly higher in ID3-
mutant Burkitt lymphoma samples relative to those with wild-type ID3 (Fig. 4b, c). Samples
with ID3 mutation also showed higher expression of known MYC target genes
(Supplementary Fig. 9). These findings provided a working hypothesis that ID3 mutations
promote the G1 to S-phase transition, which we then tested experimentally.
We designed constructs expressing six different mutant forms of the ID3 gene, encoding the
Val67*, Ile69fs, Leu64Phe, Leu54Val, Leu64His and Pro56Ser variants. We expressed these
mutant constructs using a lentiviral vector in Jijoye, a Burkitt lymphoma cell line with wild-
type ID3, and confirmed their expression using protein blot analysis and fluorescence
microscopy (Supplementary Fig. 10). Cells expressing each of the six mutant constructs had
a greater proportion of cells in S phase and a reduced proportion of cells in G1 phase (Fig.
4d), differences that, when averaged together and plotted, were significant compared to
control cells encoding wild-type ID3 (P = 0.03, paired t test; Fig. 4e). Cell-cycle analysis
over 24 h showed higher cell proliferation in all cell lines expressing mutant ID3 (P = 5.6 ×
10−5, Student's t test; Fig. 4f). These results suggest that mutations in ID3 result in increased
G1 to S-phase cell cycle progression in Burkitt lymphoma.
Conversely, when we expressed wild-type ID3 in the BL41 cell line encoding mutant ID3
(with the p.Val67* alteration), we found that the proportion of cells in S phase was lower in
cells expressing wild-type ID3 compared to control cells overexpressing only GFP (Fig.
4g,h). Similarly, we observed significantly lower cell proliferation in cells expressing wild-
type ID3 at 24 h in culture (P = 0.02, Student's t test; Fig. 4i).
Thus, ID3 mutants increased cell cycle progression and cellular proliferation in Burkitt
lymphoma cells, whereas expression of wild-type ID3 in mutant cells gave the opposite
results. These experiments support a role for ID3 as a new tumor suppressor gene in Burkitt
lymphoma.
The role of MYC as a human oncogene was first discovered in Burkitt lymphoma20, and its
importance has since been shown in a number of different malignancies, including
carcinomas of the lung21, breast22, cervix22, ovary23 and colon24. Little is known about the
role of other genetic alterations that collaborate with MYC deregulation in Burkitt
lymphoma.
Inhibitor of DNA binding (ID) proteins have been shown to be regulators of normal cellular
development25. These proteins lack a DNA-binding domain and inhibit transcription
through the formation of nonfunctional heterodimers with other basic helix-loop-helix
(bHLH) proteins. Our data implicate ID proteins, for the first time to our knowledge, in
Burkitt lymphoma and cancer, with ID3 mutations affecting over a third of Burkitt
lymphomas. Predominantly silencing mutations in ID3 were associated with increased cell
cycle progression and the expression of proliferation-associated genes. The ability of wild-
type ID3 to decrease cell proliferation in Burkitt lymphoma suggests the possibility of using
ID3 mimetics as a potential therapeutic approach in Burkitt lymphoma and other bHLH-
driven cancers. The role of ID3 also highlights the importance of context in shaping the
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effect of genetic alterations in cancer. Affecting a single gene, mutations in ID3 seem
unlikely to have a clear oncogenic role in most cancers. It is only in the setting of
deregulation of MYC (and perhaps other oncogenic bHLH proteins) that inactivating ID3
mutations might have a role by significantly amplifying the actions of these oncogenes.
Similar context-dependent roles may be carried out by a number of other oncogenes and
tumor suppressor genes.
Our study newly implicates a number of other genes in Burkitt lymphoma. Mutations in
SWI/SNF family members ARID1A and SMARCA4 occurred in a mutually exclusive
fashion in Burkitt lymphoma, affecting nearly 25% of the tumors. Lineage also seems to
have a key role in determining the mutations acquired in Burkitt lymphomas. GNA13, which
encodes a guanine nucleotide–binding G protein, was mutated through predominantly
silencing events in nearly 15% of the lymphomas and has been shown to be specifically
mutated in germinal center B cell–derived DLBCLs (ref. 26 and J.Z. et al., unpublished
data). Thus, alterations in GNA13 seem to be a germinal center B cell–specific oncogenic
event in lymphomas, similar to those described for EZH2 (ref. 26), which was also mutated
in 7% of Burkitt lymphomas. We also observed recurrent mutations in the RET, BRAF,
NOTCH1 and PI3KR1 genes and their associated pathways. These findings suggest new
therapeutic possibilities in Burkitt lymphoma that can be tested in clinical trials in
conjunction with approaches that assay for these mutations. Our data also implicate a
number of genes for the first time in cancer, including CCT6B, SALL3, FTCD and PC.
These genes likely have roles in other cancers that remain to be explored.
Exome sequencing has emerged as a powerful approach for the delineation of gene-coding
mutations in malignancies. However, this approach does not capture every important aspect
of tumor biology. Not every gene will have adequate coverage in every instance. Exome
sequencing also does not assay for structural genetic alterations, mutations in regulatory
regions and epigenetic alterations that could also make critical contributions to observed
tumor phenotypes. Nevertheless, exome sequencing provides a cost-effective means to
identify broad patterns of mutation in diseases at a resolution that was unthinkable just a few
years earlier.
Our work thus provides an important starting point for understanding the genetic landscape
of mutations in Burkitt lymphomas.
URLs
Picard, http://picard.sourceforge.net/; GATK base quality score recalibration, http://
www.broadinstitute.org/gatk; mpileup settings, http://samtools.sourceforge.net/
mpileup.shtml; Mutation Assessor, http://mutationassessor.org/; Circos, http://circos.ca/
software/download/; Novoalign V2.06.09, http://novocraft.com/; VCFtools, http://
vcftools.sourceforge.net/.
Online Methods
Sample collection and processing
Burkitt lymphoma tumors (n = 51) and normal tissues (n = 14) were obtained from the
institutions that constitute the Hematologic Malignancies Research Consortium (HMRC)27.
Information for the individuals from whom these samples were obtained is shown in
Supplementary Table 5. All tumors contained over 90% malignant cells. Samples were
anonymized, shipped to Duke University and processed in accordance with a protocol
approved by the institutional review board at Duke University. Informed consent was
obtained from all patients, except for those cases determined by the Duke Institutional
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Review Board to be exempt. In addition, eight well-characterized Burkitt lymphoma cell
lines were included in the study. Genomic DNA was extracted from the tissues and cell lines
using a previously described column-based method27.
Whole-genome sequencing
Up to 3 μg of genomic DNA from a tumor and paired normal tissue was sheared to a target
size of 500 bp using Covaris adaptive-focused acoustics with duty cycle of 5%, intensity of
3, frequency of 200 cycles/burst, duration of 80 s and water bath temperature of 4 °C. For
each sample, sheared DNA was column purified, resuspended in 10 mM Tris-HCl, pH 8.5,
and quantified on a Bioanalyzer (Agilent) using the DNA 1000 chip. DNA ends were
repaired using T4 DNA ligase, Klenow enzyme and T4 polynucleotide kinase (PNK)
(NEB), with samples incubated at 20 °C for 30 min. Poly-A tails were added to the 3′ ends
using Klenow exo‒ fragment (NEB), with samples incubated at 37 °C for 30 min. A ratio of
2 ill of Illumina paired-end adapters (J.Z. et al., unpublished data) per 1 µg of DNA was
added to the fragments using Quick Ligase (NEB), with samples incubated at 20 °C for 15
min. The library was PCR amplified for 6–8 cycles using Illumina paired-end PCR primers
and 2× Phusion High-Fidelity Master Mix (NEB). The resulting library was purified and
assayed on a Bioanalyzer to determine size and concentration. Final libraries were diluted to
5 pM for Illumina clustering, and paired-end sequencing was carried out over 9 d.
Whole-genome sequence alignment
Using the Illumina platform, we generated 178 Gb and 99 Gb of sequence from tumor and
normal samples, respectively. We estimated the average per-base sequencing coverage at
48-fold for the tumor and 26-fold for the paired germline DNA.
Reads in fastq format28 were initially processed with GATK29 version 1.0.3954 to remove
Illumina adaptor sequences (analysis type -T ClipReads, -XF illumina.adapters.fa) and
Phred-scaled base qualities of ≤10 (-QT 10). After GATK processing, reads were mapped
using the Burrows-Wheeler Aligner (BWA)30 version 0.5.8c with a -q15 setting for read
trimming, which removes the 3′ portion of reads from an alignment if it is below the quality
threshold specified. The alignments (sai files) were used to generate SAM (Sequence
Alignment/Map) paired-end read files using bwa sample and were sorted by the leftmost
coordinate with SAMtools version 0.1.12-4. All alignments were saved as BAM files31 (the
binary equivalent of the SAM format) and merged using Picard (see URLs). PCR and
optical duplicates and multiple reads likely to have been read from a single cluster on the
flow-cell image were marked with Picard. Base quality recalibration was performed using
GATK to generate a more accurate base quality score that took into account the reported
quality score in the original fastq file, position within the read and sequence context, for
example, AC and TG dinucleotides (see URLs).
To improve the accuracy and quality of the calls, localized indel realignments were
performed using GATK29, which infers the consensus indel call from multiple reads
mapping to suspected indel genomic regions, rather than considering each read
independently. Regions that needed to be realigned were identified using the GATK
Realigner Target Creator. SNVs and indel variants were called using SAMtools31. First,
reads with mapping quality of at least 1 were extracted with samtools view, and information
was collated for each base pair by genomic location using pileup. SNPs and short indels
were filtered from the pileup file using the samtools.pl v.0.3.3 helper script varFilter. Read
alignments were visualized with the Integrative Genomics Viewer (IGV)32 version 1.5.05.
The complete list of variants is documented in Supplementary Table 1.
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To compare the whole genome of the Burkitt lymphoma and its matching normal sample,
SAMtools mpileup with settings -C50 and -m3 -F0.0002 was concurrently run for the pair of
pileup files and converted to a single VCF file. The mpileup settings (see URLs) were set to
-C50 to limit the contribution of reads with many mismatches and -m3 -F0.0002 to
maximize the sensitivity of indel discovery by requiring three supporting reads at a
minimum of 0.02% abundance, rather than using the default abundance cutoff of 0.2%.
Individual SNVs and indels were annotated with gene names, and their effects on function
were predicted by the Sequence Variant Analyzer33, which uses genomic coordinates and
variants as input and yields functional annotation, including where within genes the
alteration lies (for example, in the 5′ UTR, 3′ UTR or coding sequences) and the predicted
result of the alteration (for example. amino-acid change, frameshift and stop codon gain). To
distinguish new variants discovered in our study from those previously found, all variants
were intersected with variant databases, including dbSNP135, HapMap 3 allele frequencies
and 1000 Genome Project pilot 1 allele frequencies, and Consensus Coding Sequence
(CCDS) Gene IDs were determined using BEDTools and intersectBed and formatted using
awk and custom Python scripts. Predictions of the phenotypic severity of variants not
previously annotated were determined using Mutation Assessor34 (see URLs), Polyphen-2
(ref. 35) and SIFT 36. The final variant calls are summarized in Supplementary Table 4.
Circos
Circos5 (see URLs) was used to depict the whole-genome Burkitt lymphoma copy-number
alterations and somatically acquired mutations separated by region (intergenic, regulatory
and exonic). Somatically acquired mutations in intergenic, regulatory and exonic regions
were counted in 250-kb bins and are depicted in Figure 1. Bins in which no mutations were
detected were not plotted.
Exon capture and sequencing
Up to 3 μg of genomic DNA was sheared to a target size of 250 bp by Covaris adaptive-
focused acoustics with duty cycle of 10%, intensity of 5, frequency of 200 cycles/burst,
duration of 135 s and water bath temperature of 4 °C. As in whole-genome library
preparation, purified sheared DNA was end repaired, A tailed, ligated to Illumina paired-end
adapters (J.Z. et al., unpublished data) and amplified as described in the Agilent SureSelect
Target Enrichment System for Illumina Paired-End Sequencing Library. The ligated paired-
end library was PCR amplified using Illumina paired-end PCR primers and 2× Phusion
High-Fidelity Master Mix (NEB). The library was column purified and assayed on a
Bioanalyzer to determine size and concentration.
Paired-end libraries (65 ng each) were pooled and prepared according to the protocol
provided by Agilent SureSelect Target Enrichment. They were hybridized against Agilent
SureSelect Human All Exome 50MB biotinylated baits in a thermocycler at 65 °C for 24 h.
The DNA that hybridized to baits was purified on SPRI magnetic beads (Agencourt)
according to the Agilent SureSelect protocol. The captured product was PCR amplified with
Herculase II Fusion DNA Polymerase (Stratagene) for 12 cycles, and the molarity and size
distribution were measured by Bioanalyzer using the DNA High Sensitivity chip. Captured
libraries were diluted to 5 pM for Illumina clustering, and paired-end sequencing was
carried out over 9 d.
Exome sequence alignment
Alignment steps were performed as described for whole-genome sequence processing.
Because of the shorter insert target size of this sequence relative to that generated in whole-
genome sequencing, some 100-bp paired-end reads were read through the insert and into the
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opposite adaptor. The process was modified as follows: after the first alignment step with
BWA, any discordantly mapped or unmapped read pair was extracted with SAMtools and
realigned using Novoalign V2.06.09 (see URLs), a Needleman-Wunsch algorithm–based
aligner37, with a SoftClip setting that permits clipping of the read to the best local alignment
to help align reads from shorter library inserts. Remaining unmapped reads were clipped to
35 bp to remove adaptor-matched sequence at the 3′ end of the read and realigned with
BWA. All alignments were merged using Picard.
Merging of data from different samples was performed using GATK, and variants that fell
within CCDS exons38 were then extracted using BEDTools IntersectBed39. Overlaps
between samples were computed using VCFtools (see URLs) and AWK scripts.
SAMtools pileup files were generated for all 59 Burkitt lymphomas and 14 matching normal
tissues, 94 DLBCLs and 34 matching normal tissues, and 275 control exomes from
individuals without cancer. The 275 control exomes consisted of 19 prepared in house, as
well as 256 from publicly available data sets (Supplementary Note), all of which were
processed from raw fastq sequencing reads using methods identical to those used for the
sequenced exomes.
Sequence variants were annotated by gene, and their effects on function were predicted
using the Sequence Variant Analyzer33. These data were collapsed by unique genomic
positions for intersection with known variants, as described for whole-genome analysis.
SAMtools mpileup with settings -C50 and -m3 -F0.0002 was concurrently run on data from
all lymphoma cases and used to generate a single VCF file.
Sanger sequencing validation
DNA regions of interest were amplified using primers targeting exonic regions containing
the variant (Supplementary Table 6), as described previously40. At least 50 ng of DNA was
PCR amplified using 2× HotStar Master Mix (Qiagen, 203443) and 300 nM of each primer.
A touchdown PCR method was carried out, with reactions incubated at 98 °C for 10 min and
94 °C for 2 min, followed by 10 cycles at 94 °C for 10 s, 50 °C for 1 min 10 sec and 72 °C
for 45 sec and 20 cycles at 94 °C for 15 s, 50 °C for 30 s, 74 °C for 45 sec, incremented by 5
°C per cycle, and 72 °C for 2 min 30 sec. The amplified fragments were verified by agarose
gel and purified with Agencourt Ampure XP beads according to the manufacturer's
instructions (Beckman Coulter Genomics, A63881).
Gene expression microarray analysis
Gene expression profiling on 21 Burkitt lymphomas was performed using standard
Affymetrix protocols as described previously1. Briefly, 1 μg of total RNA was reverse
transcribed, using oligo(dT) primer to synthesize cDNA. T7 primer was used for in vitro
transcription, resulting in labeled cRNA, which was fragmented and hybridized to
Affymetrix Whole-Genome Gene 1.0 ST microarrays. Microarrays were washed and
scanned, and the data were normalized as described previously27.
Expression of ID3 in cell lines
Wild-type and mutant ID3 constructs were cloned into the pLEGFP-N1 vector (BD
Biosciences) to generate GFP-fused proteins. Briefly, RT-PCR was performed using high-
capacity RNA-to-cDNA Master Mix (Applied Biosystems) on mRNA from normal lymph
node and samples from affected individuals with mutations corresponding to p.Val67*,
p.Ile69fs, p.Pro56Ser, p.Leu64His and p.Leu64Phe alterations for cDNA synthesis. ID3
mutants were PCR amplified using the ID3F and ID3R primers (Supplementary Table 6)
with Phusion High-Fidelity PCR Master Mix. PCR products were purified and digested with
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HindIII and BamHI and cloned into pLEGFP-N1 digested with the same enzymes. The
cloned ID3 mutants were confirmed by Sanger sequencing.
Viral particle production was conducted following the vendor's recommendations
(Clontech's Retroviral Gene Transfer and Expression User Manual) using ID3 constructs,
pVSV-G plasmid and the GP2-293 packaging cell line. Briefly, the packaging cell line was
transfected with ID3 constructs and pVSV-G using Lipofectamine 2000 (Invitrogen). After
48 h, the cell culture supernatant was collected and filtered through a 0.45-micron filter.
Harvested virus was used to transduce targeted cell lines. Geneticin (Invitrogen/Gibco) was
added to a final concentration of 50 μg/ml 24 h after viral transduction to select
transductants. Expression of the (wild-type or mutant) ID3-GFP fusion proteins was
confirmed by protein blot analysis and fluorescence microscopy (Supplementary Fig. 10).
Cell cycle analysis using flow cytometry
Between 1 and 2 million cells were washed 3 times in PBS containing 2% FBS. Cells were
resuspended in 0.5 ml of PBS, added dropwise to 3 ml of ice-cold 100% ethanol while
vigorously vortexing and fixed overnight at −20 °C. Cells were spun down at 250g for 5 min
and washed twice in PBS. Cell pellets were resuspended in 1 ml of pro-pidium iodide and
allowed to stain at 4 °C for 3 h. Cells were analyzed for the presence of PerCP-cy5-5-A.
FlowJo software (Tree Star) was used to generate cell cycle data and figures.
MTT cell proliferation assay
Cells were plated at equal density in a 96-well plate in 100 μl of medium. After 24 h, 10 μl
of MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) reagent was added
to the cells, which were then incubated at 37 °C for 3 h. After 3 h, 75 μl of detergent was
added, and samples were incubated for 3 h at room temperature away from light. Plates were
read at 510 nm.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Results from whole-genome sequencing of a Burkitt lymphoma tumor and germline DNA.
The Circos diagram5 summarizes the somatically acquired genetic variants in a Burkitt
lymphoma genome. The outermost ring depicts the chromosome ideogram oriented
clockwise, p terminus to q terminus. Centromeres are shown in red. The next three rings
indicate somatically acquired mutations falling in intergenic regions, potential regulatory
regions and the exome, respectively. The black arc connecting chromosomes 8 and 14
signifies a t(8;14) translocation detected in sequencing data.
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Exome sequencing in Burkitt lymphoma. (a) The ratio of somatically acquired transitions
and transversions for samples with paired normal tissue are shown for all 14 discovery set
samples. (b) The heatmap indicates the mutation patterns of the 19 most frequently
implicated genes out of the 70 genes mutated in Burkitt lymphoma. Each column represents
an affected individual, and each row represents a gene. (c) The bar graph shows the
frequency of variants found per gene across all samples, divided into nonsynonymous and
synonymous counts. (d) The bar graph shows the frequency of mutations in all 70 genes
mutated in Burkitt lymphoma in each case: orange bars represent samples in the discovery
set, and blue bars represent samples in the validation set.
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Patterns of exonic mutations in Burkitt lymphoma compared to DLBCL. (a) The bar graph
shows the proportion of Burkitt lymphoma and DLBCL samples containing a mutation in
each gene. (b) The bar graph shows the number of cases that contain a mutation in the given
gene in Burkitt lymphoma and DLBCL. (c) The heatmap shows the association between 55
genes found to be recurrently mutated in Burkitt lymphoma and/or DLBCL. Blue denotes
negative association between genes, and orange denotes positive association.
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Recurrent ID3 mutations in Burkitt lymphomas. (a) Deep sequencing reads identify
recurrent mutations affecting the HLH domain of ID3 in Burkitt lymphomas. Each colored
line represents an individual somatic mutation or a rare genetic variant. The conservation of
the HLH domain across species is also shown. Red asterisks identify the alterations that
were functionally validated. (b) The bar graph shows significantly higher expression of
genes involved in the G1 to S-phase transition in ID3-mutant Burkitt lymphoma samples
compared to those with wild-type ID3 (FDR = 0.026), as determined in gene set enrichment
analysis. Error bars, s.d. (c) Heatmap of genes corresponding to the gene set enrichment
msigdb-derived list of those involved in the G1 to S-phase transition. Red denotes high
relative expression, and green represents low relative expression across samples. (d) Cell
cycle analysis of Jijoye cells expressing mutant ID3 proteins compared to control cells
overexpressing GFP, where the red histogram denotes cells in G1 phase, orange denotes S
phase, and green denotes G2 phase. The x axis shows the relative fluorescence in the PerCP-
Cy5.5 channel. (e) The bar graph summarizes cell cycle analysis from an average of all cells
expressing ID3 mutants compared to cells overexpressing GFP (P = 0.03, χ2 test). Error
bars, s.d. (f) MTT cell proliferation assay performed on Jijoye cells expressing mutant ID3
or control GFP. Absorbance was read 24 h after plating, with higher absorbance indicating
more cells and signifying faster proliferation. Error bars, s.d. (g) Cell cycle analysis of BL41
cells expressing wild-type ID3 compared to those expressing GFP control. (h) The bar graph
summarizes cell cycle analysis for BL41 cells expressing wild-type ID3 relative to cells
expressing GFP control. (i) MTT cell proliferation assay performed on BL41 cells
expressing wild-type ID3 or GFP. Error bars, s.d.
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